Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase global visibility and influence, and further optimize its capital structure to strengthen its overall competitiveness [1] Group 1 - The company is currently in discussions with relevant intermediaries regarding the H-share listing [1] - Details of the H-share listing are yet to be determined [1] - The H-share listing plan requires approval from the company's board and shareholders, as well as necessary filings and approvals from relevant government and regulatory bodies [1]

Core Viewpoint - The company is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange [1] Group 1 - The company is currently in discussions with relevant intermediaries regarding the H-share listing [1] - Details of the H-share listing have not yet been finalized [1] - The H-share listing process requires approval from the company's board of directors and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [1]

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index closing at 3821.83 points, down by 0.18%, and a trading volume of 1,071.698 billion yuan [1] - The Shenzhen Component Index closed at 13119.82 points, down by 0.29%, with a trading volume of 1,422.684 billion yuan [1] - The ChiNext Index closed at 3114.55 points, up by 0.21%, with a trading volume of 665.817 billion yuan [1] Sector Performance - The top-performing sectors included port shipping, banking, and semiconductors, with port shipping gaining 1.43% and a total trading volume of 22,919.9 million hands [2] - The banking sector increased by 1.28%, with a total trading volume of 60,768.6 million hands [2] - The sectors that experienced the largest declines were tourism and hotels, medical services, and small metals, with tourism and hotels dropping by 5.28% [2] Detailed Sector Analysis - Port shipping sector had a net inflow of 2.79 billion yuan, with 28 stocks rising and 7 falling [2] - The banking sector saw a net inflow of 61.08 billion yuan, with 40 stocks rising and only 1 falling [2] - In contrast, the tourism and hotel sector had a net outflow of 16.76 billion yuan, with no stocks rising and 34 stocks declining [2]

Group 1 - The company has been approved to issue 145,132,743 shares at a price of RMB 5.65 per share, raising a total of approximately RMB 820 million, with a net amount of approximately RMB 802 million after deducting issuance costs [2][3] - The company has established a special account for the raised funds and signed a four-party supervision agreement with its subsidiary, the sponsor, and the bank to ensure proper management and usage of the funds [3][4] - The special account is designated solely for temporary liquidity support and cannot be used for any other purposes, ensuring compliance with regulatory requirements [3][5] Group 2 - The four-party supervision agreement includes provisions for monitoring the use of raised funds, requiring the sponsor to conduct semi-annual inspections and ensuring that any withdrawals exceeding RMB 50 million or 20% of the net raised funds are reported [5][6] - The agreement stipulates strict compliance with anti-corruption laws and regulations, prohibiting any party from soliciting or providing benefits outside the agreement [7][8] - The agreement will remain in effect until all funds are fully utilized and the account is legally closed, with any disputes to be resolved through arbitration in Shanghai [7][8]

Core Viewpoint - The current investment landscape is characterized by a new economic cycle, with significant shifts in macroeconomic analysis, particularly the need to focus on country-specific dynamics rather than solely on the US economy [2][25]. Group 1: Major Challenges in Asset Allocation - The first challenge is the misalignment of global economic cycles, where non-US developed countries' monetary policies diverge significantly from the US, influenced by de-globalization and supply chain restructuring [23][24]. - The second challenge is the decline in long-duration risk returns, driven by prolonged monetary easing in the US and increased demand for long-term bonds in China due to economic transformation and aging demographics [26][27]. - The third challenge is the simultaneous volatility of stocks and bonds in overseas markets, necessitating a greater allocation to counter-cyclical assets like gold for risk hedging [29]. Group 2: Insights on Major Asset Classes - For US dollar assets, there is potential for short-term rebounds due to economic soft landing expectations, but long-term attractiveness may diminish due to debt monetization and rising credit risks [30]. - Chinese yuan assets are expected to appreciate in the short term due to improved economic momentum and foreign capital inflows, with long-term growth potential linked to the rising importance of physical assets [30]. - The outlook for bonds remains uncertain, with US Treasury yields expected to steepen while the long-term trajectory for Chinese bonds is influenced by demographic pressures and economic structural changes [30]. Group 3: Investment Strategies and Trends - The investment strategy for cyclical stocks involves a speculative approach based on commodity price movements, which carries high risks due to the assumption of uniformity among companies within the sector [21]. - A more strategic approach involves selecting stocks with high price and income elasticity based on demand expansion trends, particularly in sectors like new energy and lightweight materials [21]. - Value-based strategies focus on identifying buying opportunities in cyclical stocks by analyzing asset elasticity, valuation levels, and demand signals [22]. Group 4: Performance of Managed Funds - The managed funds by the manager have shown significant performance, with the flagship fund achieving a return of 32.9% year-to-date and a cumulative return of 705.37% since inception [2][3]. - The investment philosophy emphasizes a balanced strategy, focusing on high-quality companies and growth stocks, with a high concentration in top holdings [4][6]. - Recent adjustments in the portfolio include increased allocations to semiconductor and biopharmaceutical sectors, reflecting a proactive approach to market trends [7][14].

Market Overview - On September 22, the biopharmaceutical sector experienced a slight decline of 0.15%, with Kanglaosheng leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aipumai (688293) with a closing price of 58.70, up 9.90% on a trading volume of 47,100 shares and a turnover of 267 million yuan [1] - Baipusais (301080) closed at 61.75, up 5.05% with a trading volume of 38,300 shares and a turnover of 231 million yuan [1] - Muli Pharmaceutical (603087) closed at 73.60, up 3.76% with a trading volume of 182,000 shares and a turnover of 134.2 million yuan [1] - Conversely, the following stocks saw significant declines: - Kanglaosheng (833575) closed at 14.71, down 6.90% with a trading volume of 90,400 shares and a turnover of 137 million yuan [2] - Kexing Pharmaceutical (688136) closed at 40.54, down 3.20% with a trading volume of 47,600 shares and a turnover of 194 million yuan [2] - Changchun High-tech (000661) closed at 122.10, down 2.49% with a trading volume of 102,800 shares and a turnover of 1.265 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 473 million yuan from institutional investors, while retail investors contributed a net inflow of 418 million yuan [2] - The following stocks had notable capital flows: - Ganli Pharmaceutical (603087) had a net inflow of 58.16 million yuan from institutional investors [3] - Rongchang Biotechnology (688331) saw a net inflow of 43.73 million yuan from institutional investors [3] - ZhiXiangJinTai (688443) had a net inflow of 6.53 million yuan from retail investors [3]

Group 1 - The company currently offers inositol as its vitamin product and plans to launch additional vitamin and amino acid products in the future [1]

Group 1 - The company Watson Bio is developing an mRNA vaccine for respiratory syncytial virus (RSV) in collaboration with partners [2] - The clinical research application for the RSV vaccine has been accepted as of August 2025 and is currently in the technical review stage [2]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The adjustment of the National Essential Medicines List (NEML) is expected to continue, with a focus on opportunities for the inclusion of traditional Chinese medicine (TCM) products [4][5][18]. - The report highlights the importance of the NEML adjustment cycle, which is generally not more than three years, and the potential for TCM products to be added to the list [5][17]. - The report suggests focusing on innovative drug research and development, particularly in TCM, and recommends specific companies as potential investment targets [19][34]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 9096.29, with a weekly high of 9323.49 and a low of 6070.89 [1]. Recent Market Performance - During the week of September 15-19, 2025, the A-share pharmaceutical and biotechnology sector fell by 2.07%, underperforming the CSI 300 index by 1.63 percentage points and the ChiNext index by 4.41 percentage points [6][20]. - The sector ranked 25th among 31 first-level sub-industries in terms of weekly performance [6]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that the innovative drug sector may experience fluctuations but emphasizes the importance of identifying high-quality assets. Recommended companies include Innovent Biologics, 3SBio, and others [7][24]. 2. **CXO Services**: The report indicates that the domestic innovative drug sector is stabilizing, with expected improvements in the CRO industry performance. Recommended companies include WuXi AppTec and Tigermed [25][26]. 3. **Biological Products**: Focus on opportunities for core product volume growth and potential valuation adjustments based on product data or business development expectations. Recommended companies include TianTan Bio and others [29]. 4. **Medical Devices**: The report anticipates a turning point in the medical device sector due to improved procurement funding and anti-corruption measures. Recommended companies include Mindray and others [30]. 5. **Traditional Chinese Medicine**: The report highlights the potential for TCM products to benefit from NEML policies and suggests companies like Zhaoke Ophthalmology and others as beneficiaries [33][34]. Market Trends - The report notes that the pharmaceutical sector's overall valuation (TTM) is 31.24, with a relative valuation premium of 136.13% compared to the CSI 300 index [44].

天眼查App显示，近日，阜阳海岳生物有限公司成立，法定代表人为韩静涛，注册资本50万人民币，经 营范围为许可项目：食品生产；食品添加剂生产；酒类经营；食品销售（依法须经批准的项目，经相关 部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）一般项目：发酵过 程优化技术研发；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；食用农产品初加 工；非食用农产品初加工；食品销售（仅销售预包装食品）；食品添加剂销售；日用百货销售；食品用 塑料包装容器工具制品销售；初级农产品收购；粮食收购；中草药收购；包装服务；信息技术咨询服务 （除许可业务外，可自主依法经营法律法规非禁止或限制的项目）。 ...